SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥142.29-CN¥0.60 (-0.42%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.09% below the high.
Loading market information…
NASDAQ · MEDP · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Medpace Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.36% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Medpace Holdings, Inc.’s next earnings report is currently expected on Feb 8, 2027, with estimated earnings per share of $4.82. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Medpace Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:16 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Jul 21, 2025 | $3.10+4.03% vs estimate | $603.31M+11.98% vs estimate |
|---|
| Q1 2025 | Apr 21, 2025 | $3.67+19.93% vs estimate | $558.57M+6.12% vs estimate |
|---|
| Q4 2024 | Feb 10, 2025 | $3.67+23.99% vs estimate | $536.59M-0.58% vs estimate |
|---|
THE ANALYST VIEW
19 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 10 contributors · Median target $672.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥142.29-CN¥0.60 (-0.42%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.09% below the high.
$275.06-$3.98 (-1.43%)
IQVIA Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.32% below the high.
$376.10+$2.12 (+0.57%)
Charles River Laboratories International, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.93% below the high.
$215.48+$1.32 (+0.62%)
ICON Public Limited Company’s quoted price sits in the upper half of its reported 52-week range, 1.61% below the high.
HK$66.75-HK$1.15 (-1.69%)
WuXi XDC Cayman Inc’s quoted price sits in the upper half of its reported 52-week range, 22.02% below the high.
CN¥39.36-CN¥0.64 (-1.6%)
Pharmaron Beijing Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 26.56% below the high.
CN¥44.03-CN¥1.75 (-3.82%)
Joinn Laboratories(China)Co.,Ltd.’s quoted price sits in the upper half of its reported 52-week range, 21.07% below the high.
$23.14-$2.75 (-10.61%)
Fortrea Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.56% below the high.
